• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

CANDESARTAN Drug Record

  • Summary
  • Interactions
  • Claims
  • CANDESARTAN chembl:CHEMBL1016

    Alternate Names:

    CV-11974
    CANDESARTAN CILEXETIL RELATED COMPOUND G
    CANDESARTAN
    2-ETHOXY-1-{[2'-(1H-TETRAZOL-5-YL)BIPHENYL-4ETHYL]}-1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID
    2-ETHOXY-1-{[2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL]METHYL}-1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID
    TCV-116 (PRODRUG)
    2-ETHOXY-1-(P-(O-1H-TETRAZOL-5-YLPHENYL)BENZYL)-7-BENZIMIDAZOLECARBOXYLIC ACID
    pubchem.compound:2541
    rxcui:214354
    drugbank:00796
    chemidplus:139481-59-7
    chembl:CHEMBL1016

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antihypertensive agent
    Year of Approval 1998
    Drug Class antihypertensive agents
    (1 More Sources)

    Publications:

    Iniesta R et al., 2019, Gene Variants at Loci Related to Blood Pressure Account for Variation in Response to Antihypertensive Drugs Between Black and White Individuals., Hypertension
    de Denus S et al., 2008, Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan., Ann Pharmacother
    McInnes et al., 2000, Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients., J Hum Hypertens
    Mendis et al., 2009, Candesartan: widening indications for this angiotensin II receptor blocker?, Expert Opin Pharmacother
    Caballero-George et al., 2003, In vitro effect of sanguinarine alkaloid on binding of [3H]candesartan to the human angiotensin AT1 receptor., Eur. J. Pharmacol.
    Baguet et al., 2009, Candesartan cilexetil in the treatment of chronic heart failure., Vasc Health Risk Manag
    Wada et al., 1996, Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats., Hypertens. Res.
    Meredith, 2007, Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure., Curr Med Res Opin
    Engelhorn et al., 2006, Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats., Neurosci. Lett.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Malmqvist et al., 2000, Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide., Am. J. Hypertens.
    Cervenka et al., 1999, Renal responses of the nonclipped kidney of two-kidney/one-clip Goldblatt hypertensive rats to type 1 angiotensin II receptor blockade with candesartan., J. Am. Soc. Nephrol.
    Vauquelin et al., 2006, Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans., J Hypertens Suppl
    Kurland L et al., 2001, Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients., J Hypertens
    Ortlepp JR et al., 2002, Variants of the CYP11B2 gene predict response to therapy with candesartan., Eur J Pharmacol
  • CANDESARTAN   SULT1C3

    Interaction Score: 13.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31327267


    Sources:
    PharmGKB

  • CANDESARTAN   SH2B3

    Interaction Score: 13.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31327267


    Sources:
    PharmGKB

  • CANDESARTAN   PLEKHJ1

    Interaction Score: 13.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31327267


    Sources:
    PharmGKB

  • CANDESARTAN   DOT1L

    Interaction Score: 6.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31327267


    Sources:
    PharmGKB

  • CANDESARTAN   GPR83

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • CANDESARTAN   CYP11B2

    Interaction Score: 3.43

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12065207


    Sources:
    PharmGKB

  • CANDESARTAN   AGTR1

    Interaction Score: 2.24

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name candesartan cilexetil,Atacand
    Novel drug target Established target

    PMIDs:
    18594050 10805052 19563275 12504781 19436650 10968199 17588300 16901636 11752352 10826401 9892163 16601569


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • CANDESARTAN   KCNK3

    Interaction Score: 1.96

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31327267


    Sources:
    PharmGKB

  • CANDESARTAN   ACE

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11593098 12065207


    Sources:
    PharmGKB

  • TEND: CANDESARTAN

    • Version: 01-August-2011

    Alternate Names:
    CANDESARTAN Primary Drug Name

    Drug Info:
    Drug Class antihypertensive agents
    Year of Approval 1998

    Publications:

  • TdgClinicalTrial: CANDESARTAN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antihypertensive agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: candesartan

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    de Denus S et al., 2008, Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan., Ann Pharmacother
    Iniesta R et al., 2019, Gene Variants at Loci Related to Blood Pressure Account for Variation in Response to Antihypertensive Drugs Between Black and White Individuals., Hypertension
    Ortlepp JR et al., 2002, Variants of the CYP11B2 gene predict response to therapy with candesartan., Eur J Pharmacol

  • TTD: Candesartan

    • Version: 2020.06.01

    Alternate Names:
    D0D5SQ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1016

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21